The corrected TIMI frame count. The new gold standard?
Over the last decade Thrombolysis in Myocardial Infarction (TIMI) flow grades have been the gold standard for the assessment of efficacy of infarct-artery reperfusion. However, with the introduction of core angiographic laboratories, the reproducibility of TIMI flow grades has been questioned. The corrected TIMI frame count (CTFC) has been developed as a more reproducible method of quantifying infarct artery blood flow after myocardial infarction (MI). We have utilised the CTFC in two studies to examine infarct-artery blood flow. In the Hirulog in Early Reperfusion and Occlusion (HERO 1) study, the CTFC was measured at 90-120 minutes after administration of aspirin, streptokinase and either Hirulog or heparin. Only 27% of patients had a normal CTFC (< or = 27) in the infarct-related artery. Patients with a prolonged CTFC (> 27) had more abnormal left ventricular function (LVF) as measured by the mean chord score in the 'area at risk' (-2.51 vs -2.06, p = 0.02), on left ventriculography. In a second study, infarct-artery flow was examined four weeks and one year after MI. At four weeks, only 43% of patients with patient infarct-related arteries had a 'normal' CTFC of < or = 27. A prolonged CTFC at four weeks was a univariate predictor of increased reocclusion at one year (p = 0.001). CTFCs are frequently abnormal in patent infarct-related arteries, and predict reocclusion. Whether frame counting is a better predictor of late clinical outcomes than the TIMI flow grade needs to be prospectively examined in large clinical trials.
Cardiology Department, Green Lane Hospital, Auckland, New Zealand.
J K
JK
French
C J
CJ
Ellis
H D
HD
White
D001783:Blood Flow Velocity / Q000187:drug effects; D002932:Cineangiography; D017023:Coronary Angiography / Q000379:methods; D003326:Coronary Circulation / Q000502:physiology; D006801:Humans; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology*; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D015912:Thrombolytic Therapy